Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomis... von Zelenetz, Andrew D, Prof, Barrientos, Jacqueline C, MD, Brown, Jennifer R, MD, Coiffier, Bertrand, Prof, Delgado, Julio, MD, Egyed, Miklós, Prof, Ghia, Paolo, MD, Illés, Árpád, Prof, Jurczak, Wojciech, MD, Marlton, Paula, MBBS, Montillo, Marco, MD, Morschhauser, Franck, Prof, Pristupa, Alexander S, MD, Robak, Tadeusz, Prof, Sharman, Jeff P, MD, Simpson, David, MBChB, Smolej, Lukáš, MD, Tausch, Eugen, MD, Adewoye, Adeboye H, MD, Dreiling, Lyndah K, MD, Kim, Yeonhee, PhD, Stilgenbauer, Stephan, Prof, Hillmen, Peter, Prof

Volltext

Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chro... von Sharman, Jeff P., Egyed, Miklos, Jurczak, Wojciech, Skarbnik, Alan, Pagel, John M., Flinn, Ian W., Kamdar, Manali, Munir, Talha, Walewska, Renata, Corbett, Gillian, Fogliatto, Laura Maria, Herishanu, Yair, Banerji, Versha, Coutre, Steven, Follows, George, Walker, Patricia, Karlsson, Karin, Ghia, Paolo, Janssens, Ann, Cymbalista, Florence, Woyach, Jennifer A., Ferrant, Emmanuelle, Wierda, William G., Munugalavadla, Veerendra, Yu, Ting, Wang, Min Hui, Byrd, John C.

Volltext

Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies von ADVANI, Ranjana H, BUGGY, Joseph J, SUKBUNTHERNG, Juthamas, IZUMI, Raquel, HAMDY, Ahmed, HEDRICK, Eric, FOWLER, Nathan H, SHARMAN, Jeff P, SMITH, Sonali M, BOYD, Thomas E, GRANT, Barbara, KOLIBABA, Kathryn S, FURMAN, Richard R, RODRIGUEZ, Sara, CHANG, Betty Y

Volltext

ABCs of ADCs in management of relapsed/refractory diffuse large B-cell lymphoma von Alderuccio, Juan Pablo, Sharman, Jeff P.

Volltext

Targeting CD20: teaching an old dog new tricks von Sharman, Jeff P

Volltext

Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 tri... von Sharman, Jeff P., Egyed, Miklos, Jurczak, Wojciech, Skarbnik, Alan, Pagel, John M., Flinn, Ian W., Kamdar, Manali, Munir, Talha, Walewska, Renata, Corbett, Gillian, Fogliatto, Laura Maria, Herishanu, Yair, Banerji, Versha, Coutre, Steven, Follows, George, Walker, Patricia, Karlsson, Karin, Ghia, Paolo, Janssens, Ann, Cymbalista, Florence, Woyach, Jennifer A., Salles, Gilles, Wierda, William G., Izumi, Raquel, Munugalavadla, Veerendra, Patel, Priti, Wang, Min Hui, Wong, Sofia, Byrd, John C.

Volltext

Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma von Tilly, Hervé, Morschhauser, Franck, Sehn, Laurie H, Friedberg, Jonathan W, Trněný, Marek, Sharman, Jeff P, Herbaux, Charles, Burke, John M, Matasar, Matthew, Rai, Shinya, Izutsu, Koji, Mehta-Shah, Neha, Oberic, Lucie, Chauchet, Adrien, Jurczak, Wojciech, Song, Yuqin, Greil, Richard, Mykhalska, Larysa, Bergua-Burgués, Juan M, Cheung, Matthew C, Pinto, Antonio, Shin, Ho-Jin, Hapgood, Greg, Munhoz, Eduardo, Abrisqueta, Pau, Gau, Jyh-Pyng, Hirata, Jamie, Jiang, Yanwen, Yan, Mark, Lee, Calvin, Flowers, Christopher R, Salles, Gilles

Volltext

Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 Study von Byrd, John C., Furman, Richard R., Coutre, Steven E., Flinn, Ian W., Burger, Jan A., Blum, Kristie, Sharman, Jeff P., Wierda, William, Zhao, Weiqiang, Heerema, Nyla A., Luan, Ying, Liu, Emily A., Dean, James P., O'Brien, Susan

Volltext

Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial von O'Brien, Susan, Prof, Furman, Richard R, MD, Coutre, Steven E, Prof, Sharman, Jeff P, MD, Burger, Jan A, MD, Blum, Kristie A, MD, Grant, Barbara, MD, Richards, Donald A, MD, Coleman, Morton, Prof, Wierda, William G, MD, Jones, Jeffrey A, MD, Zhao, Weiqiang, MD, Heerema, Nyla A, Prof, Johnson, Amy J, PhD, Izumi, Raquel, PhD, Hamdy, Ahmed, MD, Chang, Betty Y, PhD, Graef, Thorsten, MD, Clow, Fong, ScD, Buggy, Joseph J, PhD, James, Danelle F, MD, Byrd, John C, Prof

Volltext

Phase II study of acalabrutinib in ibrutinib-intolerant patients with relapsed/refractory chronic lymphocytic leukemia von Rogers, Kerry A., Thompson, Philip A., Allan, John N., Coleman, Morton, Sharman, Jeff P., Cheson, Bruce D., Jones, Daniel, Izumi, Raquel, Frigault, Melanie M., Quah, Cheng, Raman, Rakesh K., Patel, Priti, Wang, Min Hui, Kipps, Thomas J.

Volltext

Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience von O'Brien, Susan, Furman, Richard R., Coutre, Steven, Flinn, Ian W., Burger, Jan A., Blum, Kristie, Sharman, Jeff, Wierda, William, Jones, Jeffrey, Zhao, Weiqiang, Heerema, Nyla A., Johnson, Amy J., Luan, Ying, James, Danelle F., Chu, Alvina D., Byrd, John C.

Volltext

Phase 2 study of frontline brentuximab vedotin monotherapy in Hodgkin lymphoma patients aged 60 years and older von Forero-Torres, Andres, Holkova, Beata, Goldschmidt, Jerome, Chen, Robert, Olsen, Gregg, Boccia, Ralph V., Bordoni, Rodolfo E., Friedberg, Jonathan W., Sharman, Jeff P., Palanca-Wessels, Maria Corinna, Wang, Yinghui, Yasenchak, Christopher A.

Volltext

Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia von Furman, Richard R, Sharman, Jeff P, Coutre, Steven E, Cheson, Bruce D, Pagel, John M, Hillmen, Peter, Barrientos, Jacqueline C, Zelenetz, Andrew D, Kipps, Thomas J, Flinn, Ian, Ghia, Paolo, Eradat, Herbert, Ervin, Thomas, Lamanna, Nicole, Coiffier, Bertrand, Pettitt, Andrew R, Ma, Shuo, Stilgenbauer, Stephan, Cramer, Paula, Aiello, Maria, Johnson, Dave M, Miller, Langdon L, Li, Daniel, Jahn, Thomas M, Dansey, Roger D, Hallek, Michael, O'Brien, Susan M

Volltext

Final Results of a Randomized, Phase III Study of Rituximab With or Without Idelalisib Followed by Open-Label Idelalisib in Patients With Relapsed Chronic Lymphocytic Leukemia von Sharman, Jeff P, Coutre, Steven E, Furman, Richard R, Cheson, Bruce D, Pagel, John M, Hillmen, Peter, Barrientos, Jacqueline C, Zelenetz, Andrew D, Kipps, Thomas J, Flinn, Ian W, Ghia, Paolo, Eradat, Herbert, Ervin, Thomas, Lamanna, Nicole, Coiffier, Bertrand, Pettitt, Andrew R, Ma, Shuo, Tausch, Eugen, Cramer, Paula, Huang, Julie, Mitra, Siddhartha, Hallek, Michael, O'Brien, Susan M, Stilgenbauer, Stephan

Volltext

Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia von Byrd, John C, Furman, Richard R, Coutre, Steven E, Flinn, Ian W, Burger, Jan A, Blum, Kristie A, Grant, Barbara, Sharman, Jeff P, Coleman, Morton, Wierda, William G, Jones, Jeffrey A, Zhao, Weiqiang, Heerema, Nyla A, Johnson, Amy J, Sukbuntherng, Juthamas, Chang, Betty Y, Clow, Fong, Hedrick, Eric, Buggy, Joseph J, James, Danelle F, O'Brien, Susan

Volltext

Polatuzumab vedotin in combination with immunochemotherapy in patients with previously untreated diffuse large B-cell lymphoma: an open-label, non-randomised, phase 1b–2 study von Tilly, Hervé, Morschhauser, Franck, Bartlett, Nancy L, Mehta, Amitkumar, Salles, Gilles, Haioun, Corinne, Munoz, Javier, Chen, Andy I, Kolibaba, Kathryn, Lu, Dan, Yan, Mark, Penuel, Elicia, Hirata, Jamie, Lee, Calvin, Sharman, Jeff P

Volltext

Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin von Horwitz, Steven M., Advani, Ranjana H., Bartlett, Nancy L., Jacobsen, Eric D., Sharman, Jeff P., O'Connor, Owen A., Siddiqi, Tanya, Kennedy, Dana A., Oki, Yasuhiro

Volltext

Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expression von Jacobsen, Eric D., Sharman, Jeff P., Oki, Yasuhiro, Advani, Ranjana H., Winter, Jane N., Bello, Celeste M., Spitzer, Gary, Palanca-Wessels, Maria Corinna, Kennedy, Dana A., Levine, Pamela, Yang, Jing, Bartlett, Nancy L.

Volltext

A clinical practice comparison of patients with chronic lymphocytic leukemia with and without deletion 17p receiving first-line treatment with ibrutinib von Mato, Anthony R, Tang, Boxiong, Azmi, Soraya, Yang, Keri, Zhang, Xiaojuan, Stern, Jennifer C, Hedrick, Eric, Huang, Jane, Sharman, Jeff P

Volltext

Umbralisib, a Dual PI3K delta/CK1 epsilon Inhibitor in Patients With Relapsed or Refractory Indolent Lymphoma von Fowler, Nathan H., Samaniego, Felipe, Jurczak, Wojciech, Ghosh, Nilanjan, Derenzini, Enrico, Reeves, James A., Knopinska-Posluszny, Wanda, Cheah, Chan Y., Phillips, Tycel, Lech-Maranda, Ewa, Cheson, Bruce D., Caimi, Paolo F., Grosicki, Sebastian, Leslie, Lori A., Chavez, Julio C., Fonseca, Gustavo, Babu, Sunil, Hodson, Daniel J., Shao, Spencer H., Burke, John M., Sharman, Jeff P., Law, Jennie Y., Pagel, John M., Miskin, Hari P., Sportelli, Peter, O'Connor, Owen A., Weiss, Michael S., Zinzani, Pier Luigi

Volltext